Hemab Therapeutics (COAG)
Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation diso...
- Open
- 48.850
- High
- 53.000
- Low
- 46.990
- Prev. Close
- 48.200
- Volume
- 391.76K
- Turnover
- 19.21M
- Avg Price
- 49.041
- Bid/Ask Ratio
- --
- Amplitude
- 12.47%
- 52wk High
- 55.420
- Volume Ratio
- 0.80
- Turnover Ratio
- 1.93%
Hemab Therapeutics Analyst Rating
View moreForecast & Rating
Aug 11, 2026Price forecast
$61.2024.49%
Forecast & RatingStrong buy
5analysts
- Strong buy100.00%
- Buy0.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- rttnews · Aug 14 at 03:26 AM
Biotech Stocks At 52-Week Highs - PARK +10%, AVAH +24%, CADL +10% On Q2 Reports, LH, COAG
- Market Beat · Aug 12 at 11:20 AM
Hemab Therapeutics (NASDAQ:COAG) Hits New 52-Week High After Analyst Upgrade
- Market Beat · Aug 11 at 11:42 AM
Hemab Therapeutics (NASDAQ:COAG) Price Target Raised to $60.00 at HC Wainwright
- Earnings Watch · Aug 11 at 06:13 AM
Hemab Therapeutics | 8-K: FY2026 Q2 Revenue: USD 0
- PUBT · Aug 11 at 06:03 AM
Hemab Q2 FY26 net loss widens to $24.15 million; R&D expenses rise to $20.34 million
- rttnews · Aug 7 at 05:33 AM
Biotech Stocks At 52-Week Highs - DCTH +22% On Q2 Results, ANRO, COAG, MNPR, NRIX
